OTC Pharmaceuticals: North America (NAFTA) Industry Guide
The NAFTA OTC pharmaceuticals industry guide provides top-line qualitative and quantitative summary information including: market share, market size (value , and forecast to 2019). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Features and benefits
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the NAFTA OTC pharmaceuticals
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA OTC pharmaceuticals market
Leading company profiles reveal details of key OTC pharmaceuticals market players’ NAFTA operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA OTC pharmaceuticals market with five year forecasts
Compares data from the US, Canada and Mexico, alongside individual chapters on each country
The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The otc pharmaceuticals industry within the NAFTA countries had a total market value of $36,192.7 million in 2014.The Mexico was the fastest growing country, with a CAGR of 4% over the 2010-14 period. Within the otc pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $30,646.1 million in 2014. This was followed by Canada and Mexico, with a value of $3,051.0 and $2,495.6 million, respectively. The US is expected to lead the otc pharmaceuticals industry in the NAFTA bloc, with a value of $32,806.2 million in 2019, followed by Canada and Mexico with expected values of $3,544.2 and $3,058.2 million, respectively.
Your key questions answered
What was the size of the NAFTA OTC pharmaceuticals market by value in 2014?
What will be the size of the NAFTA OTC pharmaceuticals market in 2019?
What factors are affecting the strength of competition in the NAFTA OTC pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitors in the NAFTA OTC pharmaceuticals market?